Benralizumab
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Benralizumab
- Pharmacist Assessment Report
- Benralizumab: anti-IL-5Rα monoclonal antibody → Thrombocytopenia due to immune destruction
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Benralizumab: anti-IL-5Rα monoclonal antibody → Thrombocytopenia due to immune destruction
One-Sentence Summary
Benralizumab is a monoclonal antibody that targets the IL-5 receptor alpha subunit and depletes eosinophils and basophils. The TxGNN model predicts it may be effective for thrombocytopenia due to immune destruction, with a score of 0.9934. However, no clinical trials and no publications currently support this specific prediction, so it rests on computational prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 0.9934 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Benralizumab binds the IL-5 receptor alpha subunit (IL5RA) and depletes eosinophils and basophils through antibody-dependent cellular cytotoxicity (ADCC). Detailed mechanism of action data is not otherwise available in the data compiled for this report.
A link to immune-mediated thrombocytopenia is speculative. It could involve Th2/eosinophil-related immune dysregulation, but no direct mechanism is established from the available data. The high TxGNN score is a computational output only and should not be read as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered for thrombocytopenia due to immune destruction.
Literature Evidence
Currently no related literature available for thrombocytopenia due to immune destruction.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11994G | Fasenra Pen | Injection 30 mg in 1 mL single dose pre-filled pen | Not recorded in the local data |
Safety Considerations
- Drug Interactions: The only interaction record is a pharmacological one, with the target IL-5 receptor alpha subunit (IL5RA), which is the intended target of benralizumab. No drug–drug interaction with another medicine is listed.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score but no supporting clinical trials, publications or established mechanism, so it sits at evidence level L5.
To proceed, the following is needed:
- Mechanistic studies linking IL-5Rα/eosinophil biology to immune thrombocytopenia
- Preclinical or case-level evidence in immune thrombocytopenia
- Warnings and contraindications from the TGA Product Information
- Detailed mechanism of action data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.